Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Apurano Pharmaceuticals GmbH
Modality
UNKNOWN
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06071975CT.gov Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy | — | Unknown | — | — | — |
NCT06072573CT.gov Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Diabetes Mellitus
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Adezunap (this asset) | Apurano Pharmaceuticals GmbH | P3 | B · 57 |
| Metformin | Erbil Polytechnic University | P4 | A |
| Pioglitazone | Milton S. Hershey Medical Center | P4 | BBB |
| Alogliptin | Takeda | P3 | BBB |
| Glibenclamide | Takeda | P4 | BBB |
| Aspirin | Region Skane | P4 | BBB |
| Sitagliptin | Second Affiliated Hospital of Soochow University | P4 | BBB |
| Semaglutide | LMC Diabetes & Endocrinology Ltd. | P4 | BB |
| Atorvastatin | Helwan University | P4 | BB |
+41 more in the Diabetes Mellitus cohort
Other indications for Adezunap
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Diabetic Neuropathy | — | P3 | B · 60 |
| Vertebral Column Disorder | — | P3 | B · 60 |
| Diabetic Polyneuropathy | — | P3 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Adezunap in Diabetes Mellitus. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/adezunap-diabetes-mellitus
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →